The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Boytsov S.A.

National Research Centre for Preventive Medicine, Moscow, Russia

Recent trends in and new data on the epidemiology and prevention of non-communicable diseases

Authors:

Boytsov S.A.

More about the authors

Journal: Therapeutic Archive. 2016;88(1): 4‑10

Read: 2165 times


To cite this article:

Boytsov SA. Recent trends in and new data on the epidemiology and prevention of non-communicable diseases. Therapeutic Archive. 2016;88(1):4‑10. (In Russ.)
https://doi.org/10.17116/terarkh20168814-10

References:

  1. Boitsov S.A. Mekhanizmy snizheniya smertnosti ot ishemicheskoi bolezni serdtsa v raznykh stranakh mira. Profilakticheskaya meditsina. 2013;5:9-19.
  2. Boitsov S.A., Samorodskaya I.V., Tret'yakov V.V., Vatolina M.A. Poteryannye gody zhizni v rezul'tate prezhdevremennoi smerti i ikh vzaimosvyaz' s klimaticheskimi i sotsial'no-ekonomicheskimi pokazatelyami regionov. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2015; 4(70):456—463.
  3. Promezhutochnyi otchet o sotsial'nykh determinantakh i razlichiyakh po pokazatelyam zdorov'ya v Evropeiskom regione VOZ 2010. Dostupno po: http://www.euro.who.int
  4. Kontsevaya A.V., Shal'nova S.A., Balanova Yu.A., Deev A.D., Shlyakhto E.V., Boitsov S.A., Chazov E.I. Sotsial'no-ekonomicheskie gradienty povedencheskikh faktorov riska v Rossiiskoi populyatsii (po rezul'tatam issledovaniya ESSE-RF). Kardiovaskulyarnaya terapiya i profilaktika. 2015;4:59—67.
  5. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981—2000. Circulation. 2004;109:1101-1107. doi:10.1161/01.cir.0000118498.35499.b2.
  6. Bajekal M, Scholes S, Love H et al. Analysing Recent Socioeconomic Trends in Coronary Heart Disease Mortality in England, 2000—2007: A Population Modelling Study. PLoS Medicine. 2012;9:6. doi:10.1371/journal.pmed.1001237.
  7. Cooney MT, Dudina A, Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Circulation. 2010;122:300-310. doi:10.1161/circulationaha.109.852756.
  8. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15-26. doi:10.1161/01.atv.0000251503.35795.4f.
  9. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal. 2012;33:1635-1701. doi:10.1093/eurheartj/ehs092.
  10. ACC/AHA Guideline on the assessment of cardiovascular risk. Circulation. 2014;129:S49-S73.  doi:10.1161/01.cir.0000437741.48606.98.
  11. Würtz P, Havulinna AS, Soininen P et al. Metabolite Profiling and Cardiovascular Event Risk: A Prospective Study of Three Population-Based Cohorts. Circulation. 2015;131(9):774-785. doi:10.1161/circulationaha.114.013116.
  12. ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. J Am Coll Cardiol. 2010;56(25):2182-2199. doi:10.1016/j.jacc.2010.09.002.
  13. Clarke AJ, Cooper DN. GWAS: heritability missing in action? European Journal of Human Genetics. 2010;18:859-861.  doi:10.1038/ejhg.2010.35.
  14. Tennessen JA, Bigham AW, O’Connor TD et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64-69.  doi:10.1126/science.1219240.
  15. Meshkov A.N., Boitsov S.A., Ershova A.I. i dr. Issledovanie ATEROGEN-IVANOVO «Izuchenie osobennostei razvitiya i progressirovaniya ATEROskleroza razlichnoi lokalizatsii, v tom chisle s uchetom GENeticheskikh i epigeneticheskikh faktorov serdechno-sosudistogo riska — subissledovanie ESSE-IVANOVO» — dizain, algoritmy bioinformatsionnogo analiza i rezul'taty sekvenirovaniya ekzomov patsientov pilotnoi gruppy. Profilakticheskaya meditsina. 2013;6:11-20.
  16. Carrasco MP, Salvador CH, Sagredo PG et al. Impact of patient-general practitioner short-messages-based interaction on the control of hypertension in a follow-up service for low-to-medium risk hypertensive patients: a randomized controlled trial. IEEE Trans InfTechnol Biomed. 2008;12(6):780-791. doi:10.1109/titb.2008.926429.
  17. McKinstry B, Hanley J, Wild S et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013;346:f3030. doi:10.1136/bmj.f3030.
  18. Zhang XL, Zhu QQ, Zhu L et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMCMed. 2015;13:123. doi:10.1186/s12916-015-0358-8.
  19. Ahn CH, Choi SH. New drugs for treating dyslipidemia: beyond statins. Diabetes Metab J. 2015;39(2):87-94. doi:10.4093/dmj.2015.39.2.87.
  20. Lehrer-Graiwer J, Singh P, Abdelbaky A et al. FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity. J AmColl Cardiol Img. 2015;8(4):493-494. doi:10.1016/j.jcmg.2014.06.021.
  21. Nilsson J, Lichtman A, Tegui A. Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges. J Intern Med. 2015. doi:10.1111/joim.12353.
  22. Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821-827. doi:10.1016/s0140-6736(08)60381-5.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.